SR-9011 5mg/capsule, 60 caps
SR-9011 5mg/capsule, 60 caps
Currently unavailable
NovaMeds
SLU-PP-332 is a selective pan-estrogen receptor-related receptor (ERR) agonist with demonstrated activity across ERRα, ERRβ, and ERRγ subtypes.
Presentation: SLU-PP-332 (100mg/capsule), 60 Capsules.
Illustrative packaging generated with AI.
Not for human or veterinary use.
SLU-PP-332 is a selective pan-estrogen receptor-related receptor (ERR) agonist with demonstrated activity across ERRα, ERRβ, and ERRγ subtypes. The compound exhibits properties related to enhanced mitochondrial biogenesis and oxidative phosphorylation in cellular models. Each unit contains 100mg of the active molecule, supplied in 60-count containers for research applications.
The compound is intended exclusively for analytical and laboratory research purposes.
| Chemical Formula | C18H14N2O2 |
|---|---|
| Synonyms | 4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide |
| Molar Mass | 290.32 g/mol |
| CAS Number | 303760-60-3 |
| PubChem CID | 5338394 |
| Total Compound Content | 6,000 mg (100 mg per capsule) |
| Shelf Life | 36 months |
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor (ERR) subfamily, exhibiting activity across ERRα, ERRβ, and ERRγ receptor subtypes. These orphan nuclear receptors function as constitutively active transcription factors that regulate gene expression programs through interactions with coactivator proteins and transcriptional regulatory complexes. SLU-PP-332 has been characterized as a highly selective and potent pan-ERR agonist, making it a valuable research tool for investigating ERR receptor pharmacology, receptor-coactivator interactions, and nuclear receptor-mediated signaling pathways.
Results refer to the tested sample. Check the batch and date in the report.
ERRα, ERRβ, and ERRγ are orphan nuclear receptors that function as constitutively active transcription factors within the nuclear receptor superfamily. These receptors regulate gene expression through interactions with coactivator proteins and transcriptional regulatory complexes.
SLU-PP-332 is notable for exhibiting activity across all three ERR subtypes, making it a valuable research tool for investigating pan-ERR receptor pharmacology, receptor-coactivator interactions, and the coordinated regulation of ERR-dependent transcriptional signaling networks.
SLU-PP-332 possesses a highly selective pan-ERR activity profile, enabling experimental investigation of ERRα-, ERRβ-, and ERRγ-mediated signaling within a single molecular framework. This characteristic allows researchers to examine receptor activation mechanisms, coactivator recruitment processes, transcriptional control systems, and downstream regulatory pathways associated with ERR signaling.
Its well-characterized pharmacological profile has established it as an important tool for studies of orphan nuclear receptor biology.
SLU-PP-332 selectively targets the estrogen-related receptor family, whereas many other nuclear receptor agonists act through distinct receptor systems with different signaling architectures and transcriptional regulatory mechanisms. This receptor specificity makes SLU-PP-332 useful for comparative investigations of nuclear receptor pharmacology, receptor-ligand interactions, coactivator biology, and the molecular processes governing receptor-mediated transcriptional regulation.
Capsule excipients are not specified in the available product documentation.